|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-2-21
|
|
pubmed:abstractText |
To describe the clinical and histologic manifestations of skin reactions incidentally noted in patients with stage IV melanoma who were treated with up to 9 mg/kg of a humanized monoclonal antibody reactive against human cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) as a single agent every 3 weeks.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0003-987X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
142
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
166-72
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16490844-Adult,
pubmed-meshheading:16490844-Aged,
pubmed-meshheading:16490844-Antibodies, Monoclonal,
pubmed-meshheading:16490844-Antigens, CD,
pubmed-meshheading:16490844-Antigens, Differentiation,
pubmed-meshheading:16490844-Biopsy,
pubmed-meshheading:16490844-CTLA-4 Antigen,
pubmed-meshheading:16490844-Drug Eruptions,
pubmed-meshheading:16490844-Female,
pubmed-meshheading:16490844-Follow-Up Studies,
pubmed-meshheading:16490844-Humans,
pubmed-meshheading:16490844-Male,
pubmed-meshheading:16490844-Melanoma,
pubmed-meshheading:16490844-Middle Aged,
pubmed-meshheading:16490844-Neoplasm Staging,
pubmed-meshheading:16490844-Prospective Studies,
pubmed-meshheading:16490844-Severity of Illness Index,
pubmed-meshheading:16490844-Skin,
pubmed-meshheading:16490844-Skin Neoplasms,
pubmed-meshheading:16490844-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
|
|
pubmed:affiliation |
Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1908, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
